Concord Drugs Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 75.17 million compared to INR 137.16 million a year ago. Revenue was INR 75.25 million compared to INR 137.17 million a year ago. Net income was INR 5.62 million compared to INR 1.81 million a year ago. Basic earnings per share from continuing operations was INR 0.6 compared to INR 0.21 a year ago. Diluted earnings per share from continuing operations was INR 0.6 compared to INR 0.21 a year ago.
For the six months, sales was INR 164.98 million compared to INR 262.47 million a year ago. Revenue was INR 165.07 million compared to INR 262.54 million a year ago. Net income was INR 10.52 million compared to INR 3.69 million a year ago. Basic earnings per share from continuing operations was INR 1.13 compared to INR 0.42 a year ago. Diluted earnings per share from continuing operations was INR 1.13 compared to INR 0.42 a year ago.